Shutdown delays some FDA committees

Share this article:

The impact of the government shutdown is affecting FDA operations unevenly. The regulator announced Tuesday that it had approved Bayer's blood pressure drug Adempas (riociguat), which is for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).

The Center for Drug Evaluation and Research's head of cardiovascular and renal drug products said in a statement that the Bayer drug is the first in its class for pulmonary hypertension and the first of any class “shown to be effective for patients with CTEPH.” The heading of the FDA's approval notice explains how the approval got through the shutdown: user fees covered it.

Merck and Stallergenes were not so lucky. The regulator cancelled its November advisory committee panel review of their respective allergy medications Grastek and Oralair. FierceBiotech noted that Merck and Stallergenes lost out because their offerings were not new pharmaceutical products or medical devices, which means no user fee support them.

Regulatory Focus added that some recent FDA meetings which have occurred “could have benefited from the bulk of FDA's review work for those applications already completed," and notes that the 2013 user fees could run out before a budget is passed.

Reviews scheduled for this month include Gilead's sofosbuvir and Johnson & Johnson's simeprevir.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.